Floatz logo

Cyclophosphamide

Immunoproliferative Disorders

UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Immunoproliferative Disorders cohort.

Asset / SponsorPhaseRating
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B
Jcar017 (Lisocabtagene Maraleucel)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2B
Tucidinostat
Fudan University
Phase 2CCC
Atlcar.Cd30.Ccr4 Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

View all 12 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →